Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimising Renal Outcome in Myeloma Renal Failure
2012-003947-31Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Jan 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of thalidomide and bortezomib in multiple myeloma (MM) and light chain deposition disease (LCDD) (2 arms), sponsored by Oxford University Hospitals. Primary endpoint: Serum free light chain response after two cycles. Started Jan 2014; status: completed.
02
Drugs
thalidomidebortezomib
03
Conditions
multiple myeloma (MM)light chain deposition disease (LCDD)
Beyond the preview
Go deeper on 2012-003947-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003947-31.